You’ll have 1,900+ minutes to spend at ESGCT.

And we have a great suggestion for 20 of them.

Booth B10 & B12  |  Sevilla, Spain  |  October 7-11, 2025

You should expect a lot of the manufacturing partner you entrust with your AAV gene therapy. We’re up to the task. And we’d welcome a few minutes of your time at ESGCT to explain why.

text (2)

Forecast your serotype’s performance from our 1,500+ AAV runs

Group 2

Leverage our purpose-built AAV platform designed for best-in-class speed to scale

text (1)

Partner with our team of experts that has 100% success rate in IND/IMPD dossier submissions

Schedule A Meeting
César Trigueros, PhD

Presented by César Trigueros, PhD
Chief Scientific Officer, Viralgen

SESSION 6a

A Strategic Platform Roadmap for Commercializing Gene Therapy

Wednesday, October 8th, 18:00-19:30 · PARALLEL

Explore more
Webinar: Outsourced Pharma Capacity Update July 2025 - Fill/Finish
Resources
Webinar: Outsourced Pharma Capacity Update July 2025 - Fill/Finish
“May you live in interesting times.” Viralgen Chief Commercial Officer Andy Holt invokes that apocryphal “half-blessing, half-curse” as he opens his recent appearance on Outsourced Pharma Capacity Update. Andy identifies some of the key dynamics...
READ MORE
July 17, 2025
All In on Rare Disease Day 2025: Viralgen Event Highlights Critical Collaborations to Advance Successful Gene Therapies
Insights
All In on Rare Disease Day 2025: Viralgen Event Highlights Critical Collaborations to Advance Successful Gene Therapies
“Understand that we are the only ones capable of doing this task, because we’ve cared from the very beginning, because we have the capabilities, and because we can bring all the pieces together. So don't underestimate the power of what you do in the...
READ MORE
March 19, 2025
Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization
Resources
Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization
Viralgen is streamlining gene therapy manufacturing with a platform approach that accelerates timelines and reduces complexity. By leveraging process knowledge across multiple AAV serotypes, we enable faster production while ensuring quality and...
READ MORE
May 15, 2025

Fresh research on AAV manufacturing

Missed Poster Hall I2 or booth #1137 at ASGCT? Get the scoop on the latest research from the scientific and technology leads at Viralgen, who are helping shape the future of AAV-based gene therapy manufacturing.

Download the posters below to catch up.

Poster_ASGCT 2025_Viralgen_Sonia Stinus_final

Benefits of High-Throughput Sequencing-Based Methods for In-Depth Characterization of Recombinant AAV Products
Presented by Sonia Stinus, PhD.
Poster # AMA905

Integrating Raman Spectroscopy and Genome-Scale Modeling

Integrating Raman Spectroscopy and Genome-Scale Modeling to Enhance AAV Upstream Manufacturing
Presented by Itsasne Arangoa.
Poster # AMA1539

ASGCT2025_Poster_Enhancing_USP_Performance_Ainara_Apezteguia

Enhancing the Upstream Performance of Adeno-Associated Virus (AAV) Vector Manufacturing via Multivariate Data Analysis
Presented by Ainara Apezteguia.
Poster # AMA1624

Leveraging Historical Data and Percentile based Modeling FINAL

Leveraging Historical Data and Percentile based Modeling for Improved AAV Production Scaling
Presented by Itsasne Arangoa.
Poster # AMA1546

Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen

Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen
Presented by Cesar Trigueros, PhD.
Poster # AMA988

Please review the following rules: